Clinical evaluation of pipotiazine palmitate (19.552 R.P.) used on patients in an acute reception ward.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D008297:Male; D008728:Methotrimeprazine / Q000627:therapeutic use; D008875:Middle Aged; D010169:Palmitic Acids / Q000009:adverse effects / Q000627:therapeutic use; D010259:Paranoid Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D010169:Palmitic Acids; D010880:Piperidines; D013449:Sulfonamides; D008728:Methotrimeprazine; D002746:Chlorpromazine